Advertisement


Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

2024 ASCO Annual Meeting

Advertisement

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
KEYNOTE-426 was a randomized phase III trial in advanced frontline clear cell kidney cancer that randomized patients to pembrolizumab plus axitinib or sunitinib monotherapy. It was a registration trial that led to FDA approval, and the clinical data has been presented many times showing advantages to the combination arm over monotherapy and response rate, PFS and overall survival. Presented at ASCO as the first translational data from this trial. About 80 or 90% of the patients had baseline tissue that was analyzable. What was analyzed were three main things. One is RNA sequencing, looking at what's called a T-cell inflamed gene expression profile. This is a Merck-derived gene expression profile that basically defines inflammatory or hot tumors. An angiogenesis signature looking at expression of angiogenesis-related genes, and then some other various RNA-seq signatures. DNA alterations were looked at by whole exome sequencing, and what was looked at was the common alterations in kidney cancer like Von Hippel-Lindau and PBRM1 and the like. Then PDL-I staining, which has been reported before, but re-reported here was looked at in terms of the combined positive score. The translational data was linked to the five-year follow-up clinical data presented at ASCO last year and associated with outcome. The main findings were that within the pembo axitinib arm, patients who had higher expression of that T-cell-inflamed GEP, so more inflamed tumors, had better clinical outcomes, not surprisingly. In the sunitinib arm, patients who had higher expression of the angiogenesis-related genes had better clinical outcome. Again, not surprisingly. PDL-I unfortunately was not associated with outcome and it's been a fairly disappointing biomarker in kidney cancer. In terms of the non-GEP, RNA-seq signatures, not much was found. There was some association with a myeloid-derived suppressor cell signature, but it lost significance after adjusting for the T-cell-inflamed GEP, and some of the proliferative signatures were associated with worse outcome, especially in the sunitinib arm. Perhaps not surprisingly; just worse proliferative tumors that don't do as well. In terms of DNA alterations, what was seen is that there really wasn't any consistent association, and this has been seen before with DNA alterations in kidney cancer where there hasn't been good DNA alterations associated with outcome. In this analysis, within the pembro/axi arm, patients who had PBRM1 gene mutant versus wild type had about a 20% improvement in response rate, so there was some difference there. PBRM1 has been looked at in kidney cancer and had sort of variable results, so I think these contribute to those variable results. Then as mentioned, PD-L-I staining, unfortunately, was not really associated with any clinical outcome. In sum, what we see is that patients who have more inflamed tumors do better with the combination. We see higher response rates for the combination across cohorts, but again, it's sort of enriching for response within that patient population. The hard work now is really taking these results and using them prospectively. These results teach us about biology. They teach us about drug mechanism, a lot of which we knew, but I think what we really need to do is design biomarker-based trials that use, I think, baseline RNA-seq results, which I think are the most robust, assign patient's treatment based on that expression or not, and then associate that with outcome. That's how we're really going to move the field forward.

Related Videos

Skin Cancer

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Lung Cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.

Advertisement

Advertisement




Advertisement